[딜사이트 민승기 기자] Yuhan Corporation will start a free supply program (EAP) for non-small cell lung cancer treatment ‘Rexraza (ingredient name: Lazertinib)’ in earnest. Unlike normal EAP, this EAP is conducted in a way that does not limit the number of medical institutions and patients. In some hospitals, the relevant review process is nearing the end, and free supply is expected to begin this month at the earliest.
Cho Wook-je, CEO of Yuhan Corporation, held a press conference at the Plaza Hotel at 1:00 pm on the 10th to commemorate the first-line treatment approval of Lexraza (ingredient name: Lazertinib), a treatment for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer. In order to inherit the spirit of the late founder, Dr.
EAP is a program that supplies prescription drugs free of charge for compassionate purposes until they can be prescribed at the point of care after they are marketed. EAP, the first-line treatment of Lexraza implemented by Yuhan Corporation, must be reviewed and approved by the Bioethics Board (IRB) of each medical institution, followed by a thorough evaluation by the attending physician and voluntary consent of the target patient before being operated. Some hospitals are expected to release the results of the IRB review within this month.
The subjects are all patients with locally advanced or metastatic non-small cell lung cancer with an EGFR exon 19 deletion (Exon19del) or exon 21 (L858R) substitution mutation who have not previously received treatment and fall under the first-line Lexraza treatment indication. This EAP will be implemented at all secondary and tertiary medical institutions across the country that wish to prescribe Rexraza as the primary treatment. Lexraza will continue to operate until the point where benefits are expanded for primary treatment.
“Yuhan Corporation decided to implement EAP, the first-line treatment for Lexraza, in order to inherit the founding spirit of the late Dr. Il-il Yuhan,” said President Wook-Jae Jo. We want to put into practice the important ideology of giving back to society.”
The meeting also introduced Yuhan Corporation’s research and development activities to discover the 2nd and 3rd Rex Raja. Yuhan Corp. is currently focusing on three strategic disease groups: oncology, metabolism, and central nervous system (CNS) diseases, and among them, it has expressed its ambition to accelerate the development of treatments for incurable diseases through its anti-cancer pipeline.
There are 13 new drugs under development in Yuhan’s anti-cancer pipeline, in addition to Rexraza. Two of the most representative immuno-oncology double antibodies, YH32367 and YH32364, are in the clinical stage, and the remaining 11 are in the non-clinical stage. YH32367 has a mechanism of action that specifically binds to HER2-expressing tumor cells and enhances the anticancer activity of immune cells through stimulation of 4-1BB, a T immune cell activation receptor. It is expected to be effective in many solid cancer patients who are resistant to conventional chemotherapy, such as breast cancer, stomach cancer, and lung cancer. YH32364 is a bispecific antibody capable of activating target tumor-specific T-cell immunity that is effective against another carcinoma.
Oh Se-woong, vice president of Yuhan’s central research institute, said, “Yuhan is focusing on new drug development through unsparing R&D investment to discover the second and third Recraza.” We will focus on our research capabilities to remain solid as a leading company that develops medicines with
ⓒLooking at the market with new eyes. Prohibition of unauthorized reproduction and distribution of deal sites
2023-07-10 05:06:00
#Yuhan #Recraza #begins #free #supply…Inheriting #founders #spirit #Deal #Sight
